Approaches to treatment of type 2 diabetes

Diabetes Care

Volumn 31, Issue 8, 2008, Pages 1697-1703

  Bloomgarden, Zachary T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; CARBAMAZEPINE; EXENDIN 4; FELBAMATE; GABAPENTIN; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; LAMOTRIGINE; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; PREGABALIN; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE; TIAGABINE; TROGLITAZONE; UNINDEXED DRUG; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES CONTROL; DIABETIC NEPHROPATHY; DRUG MECHANISM; FLUID RETENTION; FRACTURE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIVER INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; RETINA MACULA EDEMA; SIDE EFFECT; SUICIDAL BEHAVIOR; WEIGHT GAIN; BLOOD; DRUG EFFECT; METABOLISM; NOTE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE;

EID: 49649089564     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-zb08     Document Type: Article

References (53)

1. Rosenstock J, Samols E, Muchmore DB, Schneider J, the Glimepiride Study Group: Glimepiride, a new once-daily sulfonylurea: a double-blind placebo- controlled study of NIDDM patients. Diabetes Care 19:1194-1199, 1996
2. Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT, the Glipizide Gastrointestinal Therapeutic System Study Group: Efficacy, safety, and dose- response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care 20:597-606, 1997
3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macro-vascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 12:321:405-412, 2000
4. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
5. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51: 2796-803, 2002
6. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096-1105 2006
7. Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Kawakubo M, Buchanan TA: Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gesta- tional diabetes. Diabetes 55:517-522, 2006
8. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Krawitz BG, Lachin JM, O'Neill C, Zinman B, Viberti G, for the ADOPT StudyGroup: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427-2443, 2006
9. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, De- Fronzo R, Bannayan GA, Schenker S, Cusi K: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steato-hepatitis. N Engl J Med 355:2297-2307,2006
10. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA: Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710-719, 2001
11. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA: Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:22102219, 2001
12. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 366:1279-1289, 2005
13. Bays H, Mandarino L, DeFronzo RA: Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-acti- vated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463-478, 2004
14. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
15. La Barre J, Still EU : Studies on the physiology of secretin. III. Further studies on the effects of secretin. Am J Physiol 91:649-653, 1930
16. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. JClin Endocrinol Metab 88:3082-3089, 2003
17. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, the Sitagliptin Study 020 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metforminalone. Diabetes Care 29:2638-2643, 2006
18. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, the Sitagliptin Study 021 Group: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29:2632-2637, 2006
19. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28:1556-68, 2006
20. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; Sitagliptin Study 023 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sita-gliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49: 2564-2571, 2006
21. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and micro-vascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
22. Brown JB, Nichols GA, Perry A: The burden of treatment failure in type 2 diabetes. Diabetes Care 27:1535-1540, 2004
23. Nathan DM, BuseJB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29:1963-1972, 2006
24. Turner RC, Cull CA, Frighi V, Holman RR, the UK Prospective Diabetes Study (UKPDS) Group: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 281:2005-2012, 1999
25. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
26. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL: Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147:386-399, 2007
27. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE : Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 29:2137-2139, 2006
28. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G: Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29: 554-559, 2006
29. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681-1687, 2006
30. Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglycemia Study Group: Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110:214-219, 2004
31. Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC : Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glib-enclamide in patients with maturity-onset diabetes of the young type 3. Diabetes Care 29:189-194, 2006
32. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R; American Heart Association; American Diabetes Association: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108:2941-2948, 2003
33. Huang ES, Shook M, Jin L, Chin MH, Meltzer DO: The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care 29: 259-264, 2006
34. Bloomgarden Z, Inzucchi S, Karnieli E, LeRoith D: For debate: the proposed terminology 'A1c-derived average glucose' is inherently imprecise and should not be adopted. Diabetologia 51:1111-1114, 2008
35. Nathan DM, Cleary PA, Backlund JY, Ge- nuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653, 2005
36. Grant RW, Cagliero E, Dubey AK, Gildes- game C, Chueh HC, Barry MJ, Singer DE, Nathan DM, Meigs JB: Clinical inertia in the management of type 2 diabetes metabolic risk factors. Diabet Med 21:150-155, 2004
37. Holman RR, Thorne KI, Farmer AJ, Da- vies MJ, Keenan JF, Paul S, Levy JC; 4-T Study Group: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357:17161730, 2007
38. Gilmer TP, O'Connor PJ, Manning WG, RushWA: The cost to health plans of poor glycemic control. Diabetes Care 20:1847-1853, 1997
39. CDC Diabetes Cost-effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287:2542-2551, 2002
40. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whit- comb RW, the Troglitazone Study Group: Cardiac and glycemic benefits of troglita- zone treatment in NIDDM. Diabetes 46: 433-439, 1997
41. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:1818-1820, 1998
42. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y: Rapid communication: inhibitory effect of pioglita- zone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86:3452-3456, 2001
43. Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, Fullert SD, Sachara C, Pfutzner A: Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111:2525-2531, 2005
44. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, Perez A, Provost JC, Haffner SM: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296:2572-2581, 2006
45. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC: Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24:930-934, 2004
46. Riche DM, Valderrama R, Henyan NN: Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis. Diabetes Care 30:384-388, 2007
47. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, De- Fronzo R, Bannayan GA, Schenker S, Cusi K: A placebo-controlled trial of pioglita- zone in subjects with nonalcoholic steato- hepatitis. N Engl J Med 355:2297-2307, 2006
48. Yki-Jarvinen H: Thiazolidinediones. N Engl JMed 351:1106-1118, 2004
49. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111:583-590, 2005
50. Nissen SE, Wolski K: Effect of rosiglita- zone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471, 2007
51. Machtay M, Kaiser LR, Glatstein E: Is meta-analysis really meta-physics? Chest 116:539-542, 1999
52. Diamond GA, Bax L, Kaul S: Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 147:578-581, 2007
53. Kahler KH, Rajan M, Rhoads GG, Safford MM, Demissie K, Lu SE, Pogach LM: Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care 30:1689-1693, 2007